Elon Musk's alleged drug use raises eyebrows among SpaceX, Tesla board members

Reports from the Wall Street Journal indicate growing unease among executives and board members overseeing Elon Musk's enterprises due to his alleged drug use.

Anonymous sources familiar with Musk and his businesses suggest an ongoing consumption of ketamine, despite Musk's claim last August that he holds a prescription for the drug as an antidepressant.

The report details Musk's alleged use of various substances, including LSD, cocaine, ecstasy, and psychedelic mushrooms, often in private settings. Musk's lawyer countered the claims, asserting that the billionaire undergoes regular and random drug testing at SpaceX, consistently passing without issue.

Musk's public use of marijuana alongside podcaster Joe Rogan in 2018 prompted a Pentagon review of his federal security clearance tied to his role as CEO of Space Exploration Technologies Corp.

In response to the recent allegations, Musk took to X (formerly Twitter), stating, "After that one puff with Rogan, I agreed, at NASA’s request, to do 3 years of random drug testing. Not even trace quantities were found of any drugs or alcohol."

The report also suggests that Tesla director Linda Johnson Rice, in office since 2017, chose not to seek reelection due to frustration with Musk's behaviour and alleged drug use.

Elon Musk oversees a diverse range of companies, including Tesla, SpaceX, X (formerly Twitter), The Boring Co., Neuralink, and xAI, an artificial intelligence startup. The revelation of Musk's purported drug use adds a layer of scrutiny to his leadership across these ventures.